Novartis transformation into a pure-play Innovative Medicines company

Novartis’s transformation into a pure-play Innovative Medicines company was outlined to investors by our CEO, Vas Narasimhan.
Our refreshed vision is to become the most valued and trusted medicines company in the world.
Our strategy is to deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches.
This new strategy provides a focus on core therapeutic areas (Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology), technology platforms, and priority geographies.
0:00 Evolution to pure-play
0:31 Vision
0:49 Strategy
2:14 R&D focus
3:36 Summary - top takeaways
JP Morgan Healthcare Conference
Event Date: January 9, 2023
Investors Events: bit.ly/3D1yxr5
Novartis Strategy: bit.ly/3klog2m
Disclaimer: JP Morgan healthcare conference event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: bit.ly/3kwTJyU
Follow @Novartis on Twitter: / novartis
Follow Novartis on LinkedIn: / novartis